![]() Improve data quality, enhance data lineage, and create effective data models to build business-driven data architecture with ER/Studio Data Architect. The SQL Power Architect data modeling tool was created by data warehouse designers and has many.ĭownload ModelRight and get a handle on your database immediately. SQL Power Architect Data Modeling & Profiling Tool. Erwin Data Modeler Standard Edition is a data modeling tool for organizations to launch big data intitatives and decrease data management costs. Despite higher initial reimbursement for the Zilver PTX stent, fewer expected SFA reinterventions after the primary stenting procedure result in net savings.What can we help you with? You may find a solution from the following channels. Base case results were confirmed in sensitivity analyses.Īdoption of Zilver PTX could lead to important savings for the French public health care payer. The model estimated a net cumulative 5-year budget reduction of 6,807,202 for a projected population of 82,316 patients (21,361 receiving Zilver PTX). Net budget impact was expressed as the difference in total costs (primary stenting and reinterventions) for a scenario where BMS is progressively replaced by Zilver PTX compared to a scenario of BMS only. TLR rates were based on 2-year data from the Zilver PTX single-arm study (6 and 9 %) and BMS rates reported in the literature (average 16 and 22 %) and extrapolated to 5 years. Target lesion revascularization (TLR) after primary stent placement was the primary outcome. ![]() The analysis from the payer perspective used French reimbursement tariffs. ![]() The number of patients undergoing SFA stenting was estimated on the basis of hospital episode data. This analysis assessed the likely impact on the French public health care budget of introducing reimbursement for the Zilver PTX stent.Ī model was developed in Microsoft Excel to estimate the impact of a progressive transition from BMS to Zilver PTX over a 5-year horizon. Clinical data demonstrate improved clinical outcomes compared to bare-metal stents (BMS). The Zilver PTX drug-eluting stent (Cook Ireland Ltd., Limerick, Ireland) represents an advance in endovascular treatments for atherosclerotic superficial femoral artery (SFA) disease. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |